Andrew J Belfield

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
A novel series of HDAC inhibitors demonstrating class I subtype selectivity and good oral bioavailability is described. The compounds are potent enzyme inhibitors (IC₅₀ values less than 100 nM), and(More)
  • 1